Evidence map›Paper›PMID 35862006›Full record

ArticleCirculation research2022

Unfolded Protein Response Differentially Modulates the Platelet Phenotype.

Kanika Jain, Tarun Tyagi, Jing Du, Xiaoyue Hu, Kanchi Patell, Kathleen A Martin, John Hwa

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Redox Control in Platelet Activity and Therapy.Antioxidants (Basel, Switzerland) · 2025
    Review
  8. EROdicating arterial thrombosis with a novel endoplasmic reticulum oxidoreductase 1α inhibitor.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Kanika JainYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0003-1826-4402
Tarun TyagiYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Jing DuYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Xiaoyue HuYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Kanchi PatellYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Kathleen A MartinYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-1748-0034
John HwaYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-7366-2628
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Cooperative Hematology Specialized Core CenterU54DK106857 · NIDDK · YALE UNIVERSITY · PI JOHN HWA, Diane S Krause · 2015 to 2026
$9.7M
Hyperglycemia, thromboxane and platelet activity in diabetes mellitusR01HL115247 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2012 to 2019
$3.8M
Platelet Mitochondrial Function in Health and DiseaseR01HL122815 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2015 to 2023
$3.7M
Platelets in vascular injury repairR01HL150515 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2020 to 2023
$2.3M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL115247NHLBI NIH HHS R01 HL122815NHLBI NIH HHS R01 HL150515NIDDK NIH HHS U54 DK106857
6 · The paper itself

Abstract

backgroundUnfolded protein response (UPR) is a multifaceted signaling cascade that alleviates protein misfolding. Although well studied in nucleated cells, UPR in absence of transcriptional regulation has not been described. Intricately associated with cardiovascular diseases, platelets, despite being anucleate, respond rapidly to stressors in blood. We investigate the UPR in anucleate platelets and explore its role, if any, on platelet physiology and function.

methodsHuman and mouse platelets were studied using a combination of ex vivo and in vivo experiments. Platelet lineage-specific knockout mice were generated independently for each of the 3 UPR pathways, PERK (protein kinase RNA [PKR]-like endoplasmic reticulum kinase), XBP1 (X-binding protein), and ATF6 (activating transcription factor 6). Diabetes patients were prospectively recruited, and platelets were evaluated for activation of UPR under chronic pathophysiological disease conditions.

resultsTunicamycin induced the IRE1α (inositol-requiring enzyme-1alpha)-XBP1 pathway in human and mouse platelets, while oxidative stress predominantly activated the PERK pathway. PERK deletion significantly increased platelet aggregation and apoptosis and phosphorylation of PLCγ2, PLCβ3, and p38 MAPK. Deficiency of XBP1 increased platelet aggregation, with higher PLCβ3 and PKCδ activation. ATF6 deletion mediated a relatively modest effect on platelet phenotype with increased PKA (protein kinase A). Platelets from diabetes patients exhibited a positive correlation between disease severity, platelet activation, and protein aggregation, with only IRE1α-XBP1 activation. Moreover, IRE1α inhibition increased platelet aggregation, while clinically approved chemical chaperone, sodium 4-phenylbutyrate reduced the platelet hyperactivation.

conclusionsWe show for the first time, that UPR activation occurs in platelets and can be independent of genomic regulation, with selective induction being specific to the source and severity of stress. Each UPR pathway plays a key role and can differentially modulate the platelet activation pathways and phenotype. Targeting the specific arms of UPR may provide a new antiplatelet strategy to mitigate thrombotic risk in diabetes and other cardiovascular diseases.

Indexed as

Cardiovascular DiseasesEndoribonucleasesActivating Transcription Factor 6AnimalsCyclic AMP-Dependent Protein KinaseseIF-2 KinaseEndoplasmic Reticulum StressHumansMicePhenotypeProtein Serine-Threonine KinasesUnfolded Protein ResponseX-Box Binding Protein 1Activating Transcription Factor 6Cyclic AMP-Dependent Protein KinaseseIF-2 KinaseEndoribonucleasesERN1 protein, humanErn1 protein, mouseProtein Serine-Threonine KinasesX-Box Binding Protein 1XBP1 protein, humanXbp1 protein, mouseblood plateletsdiabetes mellitusendoplasmic reticulum stressplatelet activationprotein aggregatesunfolded protein response

Identifiers

PMID35862006
PMCPMC9357223
OpenAlexW4285726944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.